ArticleAlzheimer's research & therapy2014
Assessing THK523 selectivity for tau deposits in Alzheimer's disease and non-Alzheimer's disease tauopathies.
Article in Alzheimer's research & therapy, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
34 citing papers in PubMed, 1 synthesis or guideline pooled it, 73 citations in OpenAlex.
- Pooled it
- Targeting amyloid proteins for clinical diagnosis of neurodegenerative diseases.Fundamental research · 2023Review
- The Sensitivity of Tau Tracers for the Discrimination of Alzheimer's Disease Patients and Healthy Controls by PET.Biomolecules · 2023Review
- PET molecular imaging for pathophysiological visualization in Alzheimer's disease.European journal of nuclear medicine and molecular imaging · 2023Review
- Tau Imaging in Neurodegenerative Diseases Using Positron Emission Tomography.Current neurology and neuroscience reports · 2019Review
- Frontiers in Probing Alzheimer's Disease Biomarkers with Fluorescent Small Molecules.ACS central science · 2019Review
- Innovative Molecular Imaging for Clinical Research, Therapeutic Stratification, and Nosography in Neuroscience.Frontiers in medicine · 2019Review
- Article
- The Role of Tau Imaging in Parkinsonian Disorders.Current neurology and neuroscience reports · 2018Review
- 4',6-Diamidino-2-Phenylindole Distinctly Labels Tau Deposits.The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society · 2018Article
- Development of tau PET Imaging Ligands and their Utility in Preclinical and Clinical Studies.Nuclear medicine and molecular imaging · 2018Review
- Small-molecule PET Tracers for Imaging Proteinopathies.Seminars in nuclear medicine · 2017Review
- Interactions between Microtubule-Associated Protein Tau (MAPT) and Small Molecules.Cold Spring Harbor perspectives in medicine · 2017Review
- Reference Tissue-Based Kinetic Evaluation of 18F-AV-1451 for Tau Imaging.Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2017Article
- Multiple comorbid neuropathologies in the setting of Alzheimer's disease neuropathology and implications for drug development.Alzheimer's & dementia (New York, N. Y.) · 2017Review
- Imaging tau pathology in Parkinsonisms.NPJ Parkinson's disease · 2017Review
- Genetics of Frontotemporal Dementia.Current neurology and neuroscience reports · 2016Review
- Article
- Article
- Optimization and Biodistribution of [(11)C]-TKF, An Analog of Tau Protein Imaging Agent [(18)F]-THK523.Molecules (Basel, Switzerland) · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 4 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionThe introduction of tau imaging agents such as (18)F-THK523 offers new hope for the in vivo assessment of tau deposition in tauopathies such as Alzheimer's disease (AD), where preliminary (18)F-THK523-PET studies have demonstrated significantly higher cortical retention of (18)F-THK523 in AD compared to age-matched healthy individuals. In addition to AD, tau imaging with PET may also be of value in assessing non-AD tauopathies, such as corticobasal degeneration (CBD), progressive supranuclear palsy (PSP) and Pick's disease (PiD).
methodsTo further investigate the ability of THK523 to recognize tau lesions, we undertook immunohistochemical and fluorescence studies in serial brain sections taken from individuals with AD (n = 3), CBD (n = 2), PSP (n = 1), PiD (n = 2) and Parkinson's disease (PD; n = 2). In addition to the neuropathological analysis, one PSP patient had undergone a (18)F-THK523 PET scan 5 months before death.
resultsAlthough THK523 labelled tau-containing lesions such as neurofibrillary tangles and neuropil threads in the hippocampus and frontal regions of AD brains, it failed to label tau-containing lesions in non-AD tauopathies. Furthermore, though THK523 faintly labelled dense-cored amyloid-β plaques in the AD frontal cortex, it failed to label α-synuclein-containing Lewy bodies in PD brain sections.
conclusionThe results of this study suggest that (18)F-THK523 selectively binds to paired helical filament tau in AD brains but does not bind to tau lesions in non-AD tauopathies, or to α-synuclein in PD brains.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.